- Home
- » Tags
- » Linagliptin
Top View
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Update on Insulin Management in Type 2 Diabetes
- Linagliptin Tablets First to Receive US FDA Approval at One Dosage Strength for Type 2 Diabetes Treatment
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes
- Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
- PRAC Concludes That Diabetes Medicine Canagliflozin May Contribute to Risk of Toe Amputation Risk May Also Apply to Other Medicines in the Same Class
- Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
- Hot Tip: Diabetes
- Jentadueto, INN-Linagliptin / Metformin Hydrochloride
- DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes
- Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes a $52-Week Randomized, Double-Blind Study
- Adult Type 2 Diabetes Insulin Guidelines INTRODUCTION
- Trijardy XR (Empagliflozin/Linagliptin/Metformin), an Adjunct to Diet and Exercise to Improve Glycemic Control in Adults with Type 2 Diabetes Mellitus
- Linagliptin and Pioglitazone for Diabetes
- [Product Monograph Template
- Jentadueto, INN-Linagliptin/Metformin
- Linagliptin for the Treatment of Type 2 Diabetes
- Linagliptin) Tablets Development of Blisters Or Erosions
- Diabetes Medications Timeline of Insulin Therapies in the US
- Long-Term Efficacy and Safety of Linagliptin in a Japanese
- Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin
- 204042Orig1s013
- Diabetes Medications Dosing Guide
- Objectives Disclosure
- Linagliptin and Metformin
- Tradjenta (Linagliptin)
- Therapeutic Class Review Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- JENTADUETO (Linagliptin and Metformin Hydrochloride)
- Prescribing Information
- Risk Assessment and Risk Mitigation Review(S)
- DPP-4 Inhibitors Vs. SGLT-2 Inhibitors; Cons and Pros Xourgia E, Papazafiropoulou AK*, Karampousli E and Melidonis A
- SGLT2 STEP POLICY Farxiga (Dapagliflozin), Glyxambi
- Tradjenta Generic Name: Linagliptin Manufacturer3,4,5
- FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain
- Efficacy and Safety of Canagliflozin Among Patients with Type 2
- Efficacy and Safety of Glimepiride with Or Without Linagliptin Treatment In
- Trajenta, INN-Linagliptin
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- Antihyperglycemic Agents Comparison Chart
- Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride As
- Alogliptin (Vipidia™) Sitagliptin(Januvia™) and Linagliptin (Trajenta™) for Type 2 Diabetes
- Long-Term Efficacy and Safety of Linagliptin in Patients with Type 2
- Package Leaflet: Information for the Patient Jentadueto® 2.5 Mg / 850
- 209196Orig1s000
- Efficacy and Safety of Glimepiride with Or Without Linagliptin Treatment in Patients with HNF1A Diabetes (Maturity-Onset Diabete
- Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor
- (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents with Type 2 Diabetes